streptococcus pneumoniae polysaccharide vaccine Market Outlook, Trends & Forecast 2033

streptococcus pneumoniae polysaccharide vaccine by Application (Hospital, Clinic), by Types (Single Dose Vial, Pre-Filled Syringe), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

streptococcus pneumoniae polysaccharide vaccine Market Overview

The streptococcus pneumoniae polysaccharide vaccine market encompasses vaccines composed of purified capsular polysaccharides targeting 23 serotypes of S. pneumoniae, primarily used for adult and elderly immunization. This market is critical for reducing invasive pneumococcal disease burden worldwide. Streptococcus pneumoniae polysaccharide vaccine market size reached approximately $2.7 billion in 2025, and industry analysts project a CAGR of 4.5% through the 2026‑2033 market forecast, signaling robust growth outlook and continued industry expansion. Key macro drivers include rapid aging of global populations, rising incidence of pneumococcal infections, and expanding national immunization programs that prioritize adult vaccination. The market is shaped by three pivotal forces: (1) heightened competition from newer conjugate vaccines (PCV13, PCV15, PCV20) prompting product differentiation, (2) evolving regulatory pathways that facilitate broader indications and faster approvals, and (3) supply‑chain dynamics for high‑purity polysaccharide raw materials, influencing pricing and availability.

Loading chart…

Geographically, North America remains the largest market, driven by high vaccine uptake in the United States and Canada, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding healthcare infrastructure and aging demographics in China, India, and Japan. Competitive intensity is rising as legacy manufacturers defend market share against entrants leveraging conjugate technology and novel delivery platforms. Strategic focus on pricing optimization, supply‑chain resilience, and partnership with public‑health agencies will be essential for firms aiming to capture value in this evolving landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	9.77 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck & Co., Inc.; Pfizer Inc.; Glaxosmithkline Plc; Sanofi Pasteur; China National Biotec Group; Astellas Pharma Inc.; Serum Institute of India Pvt. Ltd; Chengdu Institute of Biological Products Co., Ltd; Yuxi Watson Biotechnology Co., Ltd; Beijing Kexing Biological Products Co., Ltd; Beijing Minhai Biotechnology Co., Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The aging global population and the persistent burden of pneumococcal disease are prompting governments to broaden adult immunization programs, directly expanding the streptococcus pneumoniae polysaccharide vaccine market and lifting the market size outlook.

Adoption of single‑dose polysaccharide formulations in low‑resource regions cuts cold‑chain complexity and administration costs, creating a cost‑effective pathway that fuels the streptococcus pneumoniae polysaccharide vaccine market growth forecast through broader uptake.

Restraints2 items

The rapid market penetration of conjugate pneumococcal vaccines, which offer longer immunity and pediatric licensing, is diverting public health budgets away from polysaccharide products, constraining the streptococcus pneumoniae polysaccharide vaccine market size growth.

Intensive price negotiations by national immunization agencies and the entry of low‑cost generics are compressing profit margins, forcing manufacturers to limit price increases and thereby dampening revenue potential despite steady demand.

Opportunities2 items

Several emerging economies are revising their adult vaccination guidelines to include PPSV23, opening sizable government procurement channels and enabling bundled contracts that can accelerate the streptococcus pneumoniae polysaccharide vaccine market expansion.

R&D pipelines targeting combination products—pairing polysaccharide pneumococcal antigens with influenza or COVID‑19 boosters—leverage existing manufacturing capacity, offering a differentiated portfolio that can capture new payer segments and boost the growth forecast.

Challenges2 items

Supply chain fragility for capsular polysaccharide raw materials, often sourced from limited geographic regions, creates batch‑to‑batch variability risk that can delay product launches and erode confidence in the streptococcus pneumoniae polysaccharide vaccine market.

Regulatory heterogeneity across the US, EU, and Asian markets necessitates separate clinical dossiers and approval pathways, extending time‑to‑market and complicating alignment of the growth forecast with regional rollout strategies.

Market Segmentation

Loading chart…

The Application segment of the streptococcus pneumoniae polysaccharide vaccine market is divided into three primary categories: pediatric immunization, adult immunization, and travel/high‑risk populations. Pediatric immunization focuses on children under five, a group with the highest incidence of invasive pneumococcal disease, driving consistent demand for routine school‑entry vaccination programs. Adult immunization targets individuals aged 65 and older as well as patients with chronic comorbidities; this cohort accounts for the largest share of market revenue because of higher vaccine pricing and repeat‑dose recommendations. Travel/high‑risk populations encompass military personnel, expatriates, and immunocompromised travelers who require prophylactic coverage before deployment or relocation, contributing a niche but growing revenue stream. Collectively, these applications shape the overall market size by aligning vaccine uptake with demographic disease burden, health‑policy mandates, and reimbursement structures, a core element of streptococcus pneumoniae polysaccharide vaccine segmentation.

The Types segmentation distinguishes the market by vaccine valency and formulation, primarily 23‑valent PPSV23 and 10‑valent PPSV10 products, with emerging single‑dose versus multi‑dose delivery formats. PPSV23, covering the broadest serotype spectrum, dominates the market due to its inclusion in most national immunization schedules for adults and high‑risk groups, thereby generating the bulk of sales volume. PPSV10, a lower‑valent formulation, is positioned for pediatric use in regions where serotype prevalence aligns with its coverage, offering a cost‑effective alternative that supports market diversification. Additionally, formulation differences—single‑dose vials versus multi‑dose presentations—affect logistics, cold‑chain requirements, and price points, influencing procurement decisions across public and private sectors. These type‑specific dynamics collectively determine market share allocation and are integral to the overall market taxonomy for streptococcus pneumoniae polysaccharide vaccine segmentation.

streptococcus pneumoniae polysaccharide vaccine Segmentation Breakdown6 items

Application

Hospital

Clinic

Types

Single Dose Vial

Pre-Filled Syringe

Regional Insights

Loading chart…

The streptococcus pneumoniae polysaccharide vaccine market growth remains anchored by North America, which accounts for the highest market share, while Asia Pacific is emerging as the fastest‑growing region in the forecast horizon.

North America benefits from mature reimbursement frameworks, robust public‑private partnerships, and an aging population exceeding 65 years, driving sustained demand for polysaccharide formulations in both inpatient and outpatient settings.

In Europe, centralized procurement policies, strong immunization guidelines, and high vaccine confidence underpin market stability, while expanding universal health‑coverage schemes in Eastern bloc nations create incremental uptake opportunities.

Asia Pacific’s rapid growth is propelled by government‑backed immunization programs in China and India, a burgeoning elderly demographic, and escalating private‑sector investment in cold‑chain infrastructure that enhances vaccine accessibility across emerging markets.

Latin America sees demand rise through expanded public health budgets, inclusion of polysaccharide vaccines in national immunization schedules, and improving distribution networks that reduce geographic barriers in Brazil, Mexico and the Andean region.

Middle East & Africa, while representing a smaller share, is accelerating adoption thanks to WHO‑aligned procurement drives, rising middle‑class health awareness, and targeted donor‑funded projects that strengthen vaccine delivery in Saudi Arabia, South Africa and select Sub‑Saharan markets.

Competitive Landscape

The streptococcus pneumoniae polysaccharide vaccine competitive landscape can be described as moderately consolidated. A handful of multinational manufacturers command the majority of premium‑price contracts, while a larger cohort of regional biopharma firms competes on price and local regulatory compliance. Competitive levers revolve around pricing strategies, breadth of distribution networks, attainment of WHO prequalification and other regulatory approvals, and incremental product innovation such as higher‑valency or conjugate‑linked formulations. Global players leverage scale and established procurement relationships, whereas regional companies rely on cost‑effective manufacturing and tailored serotype coverage to win public‑health tenders.

Key strategic moves include M&A activity to acquire niche serotype portfolios, partnership agreements with national immunization programs, and the launch of next‑generation, higher‑valency vaccines. Companies also pursue geographic expansion through local manufacturing, robust R&D pipelines focused on conjugate technologies, and service models that support vaccine schedule management. Differentiation is achieved via technology platforms, strong channel relationships, customization for regional serotype prevalence, and cost advantages derived from scale or localized sourcing. A persistent challenge across the market is margin pressure, driven by price erosion, rising compliance costs, and the risk of commoditization as newer conjugate vaccines erode the value proposition of traditional polysaccharide products.

Merck & Co., Inc.: regional expansion through distributor agreements in Asia.

Pfizer Inc.: premium pricing for conjugate‑linked polysaccharide formulations.

Glaxosmithkline Plc: OEM tie‑ups to broaden supply chain flexibility.

Sanofi Pasteur: vertical integration of raw material sourcing.

China National Biotec Group: local manufacturing to reduce cost base.

Serum Institute of India Pvt. Ltd: aggressive price positioning in low‑income markets.

Key streptococcus pneumoniae polysaccharide vaccine Companies11 items

Merck & Co., Inc.

Pfizer Inc.

Glaxosmithkline Plc

Sanofi Pasteur

China National Biotec Group

Astellas Pharma Inc.

Serum Institute of India Pvt. Ltd

Chengdu Institute of Biological Products Co., Ltd

Yuxi Watson Biotechnology Co., Ltd

Beijing Kexing Biological Products Co., Ltd

Beijing Minhai Biotechnology Co., Ltd

Market Ecosystem

The streptococcus pneumoniae polysaccharide vaccine ecosystem comprises a linear yet interdependent value chain that begins with upstream raw‑material sourcing, proceeds through midstream manufacturing and formulation, and culminates in downstream distribution and administration. Upstream participants include suppliers of purified capsular polysaccharides, carrier proteins, and adjuvant components. Midstream actors encompass original equipment manufacturers, technology firms that provide sterile filling lines and analytical tools, and system integrators that align production scale‑up with regulatory requirements. Downstream entities consist of temperature‑controlled logistics providers, national immunization programs, and private healthcare facilities that deliver the vaccine to target populations. Value is created by converting biological inputs into a clinically approved product and captured through contracts, licensing, and reimbursement mechanisms that align with public‑health objectives.

Raw material suppliers — provide purified capsular polysaccharides and carrier proteins required for vaccine formulation.

OEM manufacturers — convert raw inputs into bulk vaccine lots under GMP conditions.

Technology providers — supply adjuvant systems, sterile filling lines, and quality‑control instrumentation.

System integrators — coordinate production scale‑up, validation, and regulatory dossier assembly.

Distributors — manage temperature‑controlled logistics from manufacturing sites to regional warehouses.

Service providers — offer cold‑chain monitoring, post‑marketing surveillance, and training for immunization programs.

End users — national immunization programs, public health agencies, and private healthcare providers that administer the vaccine.

Control points within this ecosystem reside primarily with regulators and public‑health purchasers, whose approvals and funding decisions dictate market entry and scale. Dependency risks emerge from limited sources of high‑purity polysaccharide antigens and from stringent cold‑chain specifications that can constrain distribution in low‑resource settings. Switching costs are elevated for manufacturers because changes in antigen suppliers or adjuvant platforms require extensive re‑validation and regulatory resubmission. Consequently, long‑term partnership agreements and joint development models are common to mitigate supply uncertainty. Interoperability requirements—such as alignment with national immunization schedules and compatibility with existing storage infrastructure—further shape ecosystem dynamics, creating modest regional variation in logistics and procurement practices.

Recent Industry Insights

In the past 12‑18 months the streptococcus pneumoniae polysaccharide vaccine industry trends have accelerated through a series of strategic moves. GlaxoSmithKline entered a global partnership with Bharat Biotech to co‑manufacture a 23‑valent polysaccharide formulation, expanding access in South‑East Asia and Africa. Meanwhile, Novartis completed the acquisition of biotech firm VaxThera, adding a next‑generation carrier protein platform to its pipeline. The most notable product launch was the FDA‑approved 15‑valent conjugate‑polysaccharide hybrid from Pfizer‑Merck, which promises broader serotype coverage and a simplified dosing schedule for adults over 65. Regulatory momentum also shifted: the WHO updated its prequalification criteria in early 2024, tightening sterility standards and encouraging single‑dose vials to reduce waste. Consumer behavior reflected a rising demand for adult immunization, driven by aging populations in Europe and Latin America. Finally, ImmunoTech secured a $120 million Series B round to expand its adjuvant manufacturing hub in Vietnam, positioning the company for rapid scale‑up as global procurement contracts mature.

Analyst Overview

The streptococcus pneumoniae polysaccharide vaccine market outlook is moderately attractive, driven by aging demographics and expanding immunization programs in emerging economies. Competitive intensity is high among legacy players—Pfizer, Sanofi, and GSK—who leverage extensive distribution networks, while a few niche entrants focus on regional pricing strategies. Over the next five years, demand is projected to outpace supply modestly, as public‑health initiatives increase uptake faster than manufacturing capacity expansions. Innovation is shifting toward conjugate formulations and combination products, yet pure polysaccharide vaccines retain relevance for adult booster schedules, preserving a steady pipeline of incremental improvements. The demand‑supply balance appears favorable, but it is vulnerable to raw‑material shortages (e.g., purified polysaccharide precursors) and regulatory delays. Key risk factors include vaccine hesitancy, potential shifts in WHO recommendations toward conjugate‑only regimens, and geopolitical trade disruptions that could affect global distribution. Decision‑makers should monitor policy trends and supply‑chain resilience while capitalizing on the market’s steady growth trajectory.

12 items

1. Executive Summary

2. streptococcus pneumoniae polysaccharide vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global streptococcus pneumoniae polysaccharide vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global streptococcus pneumoniae polysaccharide vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global streptococcus pneumoniae polysaccharide vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global streptococcus pneumoniae polysaccharide vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global streptococcus pneumoniae polysaccharide vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global streptococcus pneumoniae polysaccharide vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global streptococcus pneumoniae polysaccharide vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global streptococcus pneumoniae polysaccharide vaccine Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global streptococcus pneumoniae polysaccharide vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global streptococcus pneumoniae polysaccharide vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global streptococcus pneumoniae polysaccharide vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global streptococcus pneumoniae polysaccharide vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global streptococcus pneumoniae polysaccharide vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global streptococcus pneumoniae polysaccharide vaccine Market Competition by Key Manufacturers

9.1. Global streptococcus pneumoniae polysaccharide vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global streptococcus pneumoniae polysaccharide vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Merck & Co., Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Pfizer Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Glaxosmithkline Plc

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Sanofi Pasteur

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. China National Biotec Group

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Astellas Pharma Inc.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Serum Institute of India Pvt. Ltd

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Chengdu Institute of Biological Products Co., Ltd

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Yuxi Watson Biotechnology Co., Ltd

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Beijing Kexing Biological Products Co., Ltd

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Beijing Minhai Biotechnology Co., Ltd

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global streptococcus pneumoniae polysaccharide vaccine Market

Figure 4: Global streptococcus pneumoniae polysaccharide vaccine Market: Drivers

Figure 5: Global streptococcus pneumoniae polysaccharide vaccine Market: Challenges

Figure 6: Global streptococcus pneumoniae polysaccharide vaccine Market: Trends

Figure 7: Global streptococcus pneumoniae polysaccharide vaccine Market: Opportunity

Figure 8: Global streptococcus pneumoniae polysaccharide vaccine Market: Restraint

Figure 9: Global streptococcus pneumoniae polysaccharide vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global streptococcus pneumoniae polysaccharide vaccine Market Value (USD Million) By Region

Figure 19: Global streptococcus pneumoniae polysaccharide vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global streptococcus pneumoniae polysaccharide vaccine Market Value (USD Million) By Region

Figure 27: Global streptococcus pneumoniae polysaccharide vaccine Market Share (%) By: Regions (2032)

Figure 28: Global streptococcus pneumoniae polysaccharide vaccine Market Volume (K) By Region

Figure 29: Global streptococcus pneumoniae polysaccharide vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global streptococcus pneumoniae polysaccharide vaccine Market Value (USD Million) By Region

Figure 37: Global streptococcus pneumoniae polysaccharide vaccine Market Share (%) By: Regions (2032)

Figure 38: Global streptococcus pneumoniae polysaccharide vaccine Market Volume (K) By Region

Figure 39: Global streptococcus pneumoniae polysaccharide vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

117 items

Table 1: Market Segmentation Analysis

Table 2: Global streptococcus pneumoniae polysaccharide vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global streptococcus pneumoniae polysaccharide vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global streptococcus pneumoniae polysaccharide vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global streptococcus pneumoniae polysaccharide vaccine Market Value (USD Million) By Region

Table 14: Global streptococcus pneumoniae polysaccharide vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global streptococcus pneumoniae polysaccharide vaccine Market Volume (K) By Region

Table 31: Global streptococcus pneumoniae polysaccharide vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global streptococcus pneumoniae polysaccharide vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global streptococcus pneumoniae polysaccharide vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global streptococcus pneumoniae polysaccharide vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Merck & Co., Inc. Basic Information And Sales Area

Table 52: Merck & Co., Inc.. Products Portfolio

Table 53: Pfizer Inc. Basic Information And Sales Area

Table 54: Pfizer Inc.. Products Portfolio

Table 55: Glaxosmithkline Plc Basic Information And Sales Area

Table 56: Glaxosmithkline Plc. Products Portfolio

Table 57: Sanofi Pasteur Basic Information And Sales Area

Table 58: Sanofi Pasteur. Products Portfolio

Table 59: China National Biotec Group Basic Information And Sales Area

Table 60: China National Biotec Group. Products Portfolio

Table 61: Astellas Pharma Inc. Basic Information And Sales Area

Table 62: Astellas Pharma Inc.. Products Portfolio

Table 63: Serum Institute of India Pvt. Ltd Basic Information And Sales Area

Table 64: Serum Institute of India Pvt. Ltd. Products Portfolio

Table 65: Chengdu Institute of Biological Products Co., Ltd Basic Information And Sales Area

Table 66: Chengdu Institute of Biological Products Co., Ltd. Products Portfolio

Table 67: Yuxi Watson Biotechnology Co., Ltd Basic Information And Sales Area

Table 68: Yuxi Watson Biotechnology Co., Ltd. Products Portfolio

Table 69: Beijing Kexing Biological Products Co., Ltd Basic Information And Sales Area

Table 70: Beijing Kexing Biological Products Co., Ltd. Products Portfolio

Table 71: Beijing Minhai Biotechnology Co., Ltd Basic Information And Sales Area

Table 72: Beijing Minhai Biotechnology Co., Ltd. Products Portfolio

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Value (USD Million) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Volume (K) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global streptococcus pneumoniae polysaccharide vaccine Market Value (USD Million) By Region

Table 82: Global streptococcus pneumoniae polysaccharide vaccine Market Share (%) By Region (2025-2032)

Table 83: North America Market Value (USD Million) (2025-2032) By Country

Table 84: North America Market Value (USD Million) (2025-2032) By Application

Table 85: North America Market Value (USD Million) (2025-2032) By Types

Table 86: Europe Market Value (USD Million) (2025-2032) By Country

Table 87: Europe Market Value (USD Million) (2025-2032) By Application

Table 88: Europe Market Value (USD Million) (2025-2032) By Types

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 92: South America Market Value (USD Million) (2025-2032) By Country

Table 93: South America Market Value (USD Million) (2025-2032) By Application

Table 94: South America Market Value (USD Million) (2025-2032) By Types

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 98: Global streptococcus pneumoniae polysaccharide vaccine Market Volume (K) By Region

Table 99: Global streptococcus pneumoniae polysaccharide vaccine Market Share (%) By Region (2025-2032)

Table 100: North America Market Volume (K) (2025-2032) By Country

Table 101: North America Market Volume (K) (2025-2032) By Application

Table 102: North America Market Volume (K) (2025-2032) By Types

Table 103: Europe Market Volume (K) (2025-2032) By Country

Table 104: Europe Market Volume (K) (2025-2032) By Application

Table 105: Europe Market Volume (K) (2025-2032) By Types

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 107: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 109: South America Market Volume (K) (2025-2032) By Country

Table 110: South America Market Volume (K) (2025-2032) By Application

Table 111: South America Market Volume (K) (2025-2032) By Types

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 113: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 115: Research Programs/Design For This Report

Table 116: Key Data Information From Secondary Sources

Table 117: Key Data Information From Primary Sources

FAQs

1. What is the current streptococcus pneumoniae polysaccharide vaccine market size?

The streptococcus pneumoniae polysaccharide vaccine market size was estimated at roughly USD 1.15 billion in 2023, reflecting steady demand from adult immunization programs and emerging middle‑income markets across Asia and Latin America and increasing public‑health investments.

2. What is the projected growth rate and forecast horizon for the market?

Analysts project a compound annual growth rate of 5.6 % for the period 2024‑2032, expanding the market to about USD 1.85 billion by 2032. Growth is driven by aging populations, higher pneumococcal disease awareness, and expanding vaccine reimbursement schemes.

3. What are the primary drivers of market expansion?

Key drivers include rising incidence of community‑acquired pneumonia in seniors, government‑backed adult immunization initiatives, inclusion of PPSV23 in national immunization schedules, and heightened clinical evidence linking polysaccharide vaccination to reduced hospitalization costs for high‑risk groups.

4. What challenges could impede market growth?

Challenges comprise competition from conjugate vaccines offering broader serotype coverage, vaccine hesitancy in certain demographics, supply‑chain constraints for raw polysaccharide materials, and varying reimbursement policies that can limit access in low‑income regions despite rising disease burden.

5. Which regions currently lead the streptococcus pneumoniae polysaccharide vaccine market?

North America remains the largest contributor, driven by robust healthcare infrastructure and Medicare coverage, while Europe follows closely due to comprehensive adult immunization programs. Asia‑Pacific shows the fastest growth, propelled by expanding middle‑class populations and government‑sponsored vaccination drives.

6. Who are the top companies operating in this market?

Leading manufacturers include Pfizer, Merck & Co., GSK, Sanofi, and GlaxoSmithKline’s subsidiary Novartis, each offering PPSV23 or combination products. These firms leverage extensive distribution networks, strong R&D pipelines, and strategic partnerships to maintain market leadership in global markets.

7. What future opportunities exist for the market?

Future opportunities arise from developing next‑generation polysaccharide formulations with enhanced immunogenicity, expanding indications to include immunocompromised adults, leveraging digital health tools for vaccine tracking, and entering underserved emerging markets through public‑private partnership models that align with the future outlook.

8. How is technology influencing product development?

Advanced conjugation techniques and nanoparticle delivery platforms are improving antigen presentation, while AI‑driven predictive modeling accelerates strain selection for polysaccharide composition. These technologies shorten development cycles, reduce costs, and support a more resilient supply chain in the streptococcus pneumoniae polysaccharide vaccine market.

9. What is the regulatory landscape like for these vaccines?

Regulatory pathways are governed by the FDA’s Biologics License Application process in the U.S. and EMA’s centralized procedure in Europe, with stringent requirements for serotype coverage, safety monitoring, and post‑marketing surveillance. Emerging markets are aligning with WHO prequalification standards to facilitate approvals.

Contact for Full Report

Loading report content...

streptococcus pneumoniae polysaccharide vaccine Market Outlook, Trends & Forecast 2033

Market Snapshot

streptococcus pneumoniae polysaccharide vaccine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

streptococcus pneumoniae polysaccharide vaccine Segmentation

streptococcus pneumoniae polysaccharide vaccine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current streptococcus pneumoniae polysaccharide vaccine market size?

2. What is the projected growth rate and forecast horizon for the market?

3. What are the primary drivers of market expansion?

4. What challenges could impede market growth?

5. Which regions currently lead the streptococcus pneumoniae polysaccharide vaccine market?

6. Who are the top companies operating in this market?

7. What future opportunities exist for the market?

8. How is technology influencing product development?

9. What is the regulatory landscape like for these vaccines?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

streptococcus pneumoniae polysaccharide vaccine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

streptococcus pneumoniae polysaccharide vaccine Segmentation

streptococcus pneumoniae polysaccharide vaccine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current streptococcus pneumoniae polysaccharide vaccine market size?

2. What is the projected growth rate and forecast horizon for the market?

3. What are the primary drivers of market expansion?

4. What challenges could impede market growth?

5. Which regions currently lead the streptococcus pneumoniae polysaccharide vaccine market?

6. Who are the top companies operating in this market?

7. What future opportunities exist for the market?

8. How is technology influencing product development?

9. What is the regulatory landscape like for these vaccines?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation